DCZ0415 is primarily recognized for its role as a potent and selective inhibitor of the proteasome, a complex responsible for protein degradation in cells. Its application is significant in the field of cancer research, where it is studied for its potential to induce apoptosis in cancerous cells by disrupting proteasome function. This mechanism is particularly relevant in treating multiple myeloma and other hematologic malignancies, as it targets the uncontrolled protein turnover that supports tumor growth. Additionally, DCZ0415 is being explored for its synergistic effects when combined with other anticancer therapies, enhancing their efficacy. Its ability to modulate proteasome activity also makes it a valuable tool in understanding cellular processes and protein homeostasis in various diseases.